Theranostic Nanomedicine for Malignant Gliomas.

brain tumors diagnosis drug delivery targeted therapy theranostic nanoplatform

Journal

Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513

Informations de publication

Date de publication:
2019
Historique:
received: 29 07 2019
accepted: 28 10 2019
entrez: 5 12 2019
pubmed: 5 12 2019
medline: 5 12 2019
Statut: epublish

Résumé

Brain tumors mainly originate from glial cells and are classified as gliomas. Malignant gliomas represent an incurable disease; indeed, after surgery and chemotherapy, recurrence appears within a few months, and mortality has remained high in the last decades. This is mainly due to the heterogeneity of malignant gliomas, indicating that a single therapy is not effective for all patients. In this regard, the advent of theranostic nanomedicine, a combination of imaging and therapeutic agents, represents a strategic tool for the management of malignant brain tumors, allowing for the detection of therapies that are specific to the single patient and avoiding overdosing the non-responders. Here, recent theranostic nanomedicine approaches for glioma therapy are described.

Identifiants

pubmed: 31799246
doi: 10.3389/fbioe.2019.00325
pmc: PMC6868071
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

325

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2019 d'Angelo, Castelli, Benedetti, Antonosante, Catanesi, Dominguez-Benot, Pitari, Ippoliti and Cimini.

Références

Cell Cycle. 2012 Mar 15;11(6):1202-16
pubmed: 22391209
Cell. 1998 Oct 2;95(1):29-39
pubmed: 9778245
Mol Pharm. 2010 Dec 6;7(6):1879
pubmed: 21128687
Nanotheranostics. 2017 Mar 3;1(1):131-140
pubmed: 29071182
Cancers (Basel). 2019 Jan 18;11(1):
pubmed: 30669406
Materials (Basel). 2018 May 11;11(5):
pubmed: 29751640
Biomaterials. 2009 May;30(15):2919-28
pubmed: 19230966
Bioconjug Chem. 2011 Oct 19;22(10):1879-903
pubmed: 21830812
Adv Mater. 2012 Jul 24;24(28):3779-802
pubmed: 22610698
Nat Nanotechnol. 2007 Dec;2(12):751-60
pubmed: 18654426
J Cell Physiol. 2017 Feb;232(2):312-322
pubmed: 27171480
Biomaterials. 2012 Apr;33(11):3324-33
pubmed: 22281423
Pharmacol Res. 2017 Jan;115:87-95
pubmed: 27865762
Ther Deliv. 2013 Jun;4(6):687-704
pubmed: 23738667
Biomaterials. 2012 Jan;33(3):856-66
pubmed: 22036101
Clin Cancer Res. 2001 Feb;7(2):243-54
pubmed: 11234875
JAMA Oncol. 2017 Aug 01;3(8):1094-1101
pubmed: 28426845
Cancer Epidemiol Biomarkers Prev. 2014 Oct;23(10):1985-96
pubmed: 25053711
Nano Lett. 2004 Jan 1;4(1):11-18
pubmed: 28890669
J Control Release. 2017 Oct 28;264:102-111
pubmed: 28842313
PLoS One. 2013 Apr 30;8(4):e62425
pubmed: 23638079
Expert Rev Anticancer Ther. 2015;15(10):1233-55
pubmed: 26402250
J Mater Chem B. 2015 Apr 28;3(16):3297-3305
pubmed: 32262324
Cancer Res. 2002 Jan 1;62(1):200-7
pubmed: 11782378
J Biomed Nanotechnol. 2016 Feb;12(2):347-56
pubmed: 27305768
Nanoscale. 2015 Feb 7;7(5):1782-90
pubmed: 25519743
Mol Pharm. 2010 Dec 6;7(6):1899-912
pubmed: 20822168
Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14720-5
pubmed: 11121071
Mol Pharm. 2014 Jul 7;11(7):2346-57
pubmed: 24893333
Mol Pharm. 2014 Jul 7;11(7):1949-63
pubmed: 24641309
J Control Release. 2018 May 10;277:89-101
pubmed: 29522834
Adv Drug Deliv Rev. 2011 Aug 14;63(9):772-88
pubmed: 21554908
Semin Cancer Biol. 2009 Feb;19(1):4-11
pubmed: 19101633
Biochem Biophys Res Commun. 2015 Dec 18;468(3):419-27
pubmed: 26168726
Cancer Treat Rev. 2002 Apr;28(2):115-20
pubmed: 12297119
Curr Opin Drug Discov Devel. 2010 Jan;13(1):111-23
pubmed: 20047152
Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3749-54
pubmed: 21321221
Nat Rev Cancer. 2004 Nov;4(11):891-9
pubmed: 15516961
Clin Radiol. 2010 Jul;65(7):500-16
pubmed: 20541650
Acta Biomater. 2018 Jun;73:52-63
pubmed: 29678675
Colloids Surf B Biointerfaces. 2016 May 1;141:429-442
pubmed: 26895505
Br J Radiol. 2012 Sep;85(1017):e729-33
pubmed: 22215883
Neuro Oncol. 2016 May;18(5):691-9
pubmed: 26519740
Colloids Surf B Biointerfaces. 2011 May 1;84(1):82-7
pubmed: 21251801
J Control Release. 2015 Feb 28;200:138-57
pubmed: 25545217
Int J Mol Sci. 2018 Jun 29;19(7):
pubmed: 29966227
Mol Cancer Ther. 2006 Nov;5(11):2624-33
pubmed: 17121909
Lancet. 2003 Jan 25;361(9354):323-31
pubmed: 12559880
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4240-5
pubmed: 10200246
Stem Cells Int. 2016;2016:6809105
pubmed: 26880981
Mater Sci Eng C Mater Biol Appl. 2017 Sep 1;78:32-38
pubmed: 28575990
Rev Med Liege. 2008 May-Jun;63(5-6):251-6
pubmed: 18669189
Oncogene. 2009 Nov 12;28(45):4009-21
pubmed: 19718054
Adv Drug Deliv Rev. 2006 Dec 1;58(14):1556-77
pubmed: 17107738
Adv Drug Deliv Rev. 2006 Oct 1;58(8):962-74
pubmed: 16996642
Neuropathol Appl Neurobiol. 2018 Feb;44(2):139-150
pubmed: 28815663
Int J Pharm. 2017 Oct 5;531(1):389-410
pubmed: 28801108
Mol Pharm. 2013 Mar 4;10(3):793-812
pubmed: 23294202
J Am Chem Soc. 2012 May 2;134(17):7414-22
pubmed: 22486413
Oncotarget. 2018 Jan 3;9(6):6883-6896
pubmed: 29467937
J Biomed Biotechnol. 2012;2012:672760
pubmed: 22665988
Mol Pharm. 2015 Sep 8;12(9):3250-60
pubmed: 26198693
Adv Funct Mater. 2014 Jul 16;24(27):4206-4220
pubmed: 25477774
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Theranostics. 2015 Feb 20;5(6):559-82
pubmed: 25825597
Clin Cancer Res. 2004 Nov 1;10(21):7157-62
pubmed: 15534087
Adv Drug Deliv Rev. 2015 Dec 1;95:2-14
pubmed: 26344675
J Nanosci Nanotechnol. 2015 Aug;15(8):5501-11
pubmed: 26369109
Adv Drug Deliv Rev. 2017 Jan 1;108:25-38
pubmed: 27137110
ACS Nano. 2014 Oct 28;8(10):10655-64
pubmed: 25259648
Acc Chem Res. 2011 Oct 18;44(10):1050-60
pubmed: 21919457
FASEB J. 2008 Jul;22(7):2243-52
pubmed: 18263700
J Food Drug Anal. 2014 Mar;22(1):3-17
pubmed: 24673900
Theranostics. 2018 Feb 5;8(6):1481-1493
pubmed: 29556336
Mater Sci Eng C Mater Biol Appl. 2017 May 1;74:167-176
pubmed: 28254282
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
J Mater Chem B. 2013 Jul 7;1(25):3128-3135
pubmed: 32260912
Chem Soc Rev. 2004 Jan 10;33(1):43-63
pubmed: 14737508
Cell. 2000 Oct 13;103(2):211-25
pubmed: 11057895
Int J Pharm. 2011 Sep 20;416(2):443-7
pubmed: 21315141
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2965-9
pubmed: 1557402
Nanotheranostics. 2018 Jan 1;2(1):70-86
pubmed: 29291164
Drug Resist Updat. 2011 Jun;14(3):150-63
pubmed: 21330184
Biomaterials. 2008 Feb;29(4):487-96
pubmed: 17964647
Nano Res. 2010 Oct 1;3(11):779-793
pubmed: 21804931
Drug Deliv. 2016 Jun;23(5):1788-98
pubmed: 26431064
Sci Rep. 2014 Nov 14;4:7057
pubmed: 25394758
Int J Pharm. 2015 Mar 15;481(1-2):154-61
pubmed: 25644286
Adv Drug Deliv Rev. 2010 Aug 30;62(11):1064-79
pubmed: 20691229
Drug Discov Today. 2012 Sep;17(17-18):928-34
pubmed: 22484464
Materials (Basel). 2019 May 15;12(10):
pubmed: 31096609
Neurosurg Rev. 2015 Jan;38(1):27-37; discussion 37
pubmed: 25173621
J Cereb Blood Flow Metab. 2016 May;36(5):862-90
pubmed: 26868179
Mol Pharm. 2010 Aug 2;7(4):969-83
pubmed: 20524664
J Colloid Interface Sci. 2011 Nov 1;363(1):403-9
pubmed: 21821262
Acc Chem Res. 2011 Oct 18;44(10):893-902
pubmed: 21848274
FASEB J. 2008 Dec;22(12):4179-89
pubmed: 18697838
Nanomedicine (Lond). 2010 Nov;5(9):1401-14
pubmed: 21128722
Nanoscale. 2012 Jan 21;4(2):330-42
pubmed: 22134683
Expert Rev Neurother. 2008 Oct;8(10):1457-73
pubmed: 18928341
J Control Release. 2011 Jan 20;149(2):111-6
pubmed: 20888381
ACS Nano. 2008 May;2(5):889-96
pubmed: 19206485
Oncol Rev. 2019 Jul 25;13(2):417
pubmed: 31410248
Acc Chem Res. 2011 Oct 18;44(10):1094-104
pubmed: 21812415
Colloids Surf B Biointerfaces. 2016 Nov 1;147:129-141
pubmed: 27497076
Nano Lett. 2005 Feb;5(2):331-8
pubmed: 15794621
Trends Mol Med. 2008 May;14(5):228-35
pubmed: 18403264
Chem Soc Rev. 2011 Jan;40(1):173-90
pubmed: 20877875
Neurol Sci. 2018 Dec;39(12):2021-2031
pubmed: 30327956
Biotechnol Adv. 2013 Sep-Oct;31(5):593-606
pubmed: 23111203
Biomaterials. 2011 Jan;32(2):528-37
pubmed: 20869767
Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):781-6
pubmed: 14711994
Nat Biomed Eng. 2017 Oct;1(10):796-806
pubmed: 31015588
Drug Deliv. 2016 May;23(4):1261-71
pubmed: 26961144
Acc Chem Res. 2011 Oct 18;44(10):883-92
pubmed: 21548618
Drug Deliv. 2016 May;23(4):1369-73
pubmed: 26017099
Biomaterials. 2013 Jan;34(4):1193-203
pubmed: 23168385
Int J Pharm. 2017 Jun 30;526(1-2):380-390
pubmed: 28465052
Biomaterials. 2011 Oct;32(30):7600-8
pubmed: 21745689
Nanomedicine (Lond). 2013 Oct;8(10):1601-9
pubmed: 23265347
Biomaterials. 2013 Feb;34(7):1772-80
pubmed: 23228423
Nat Rev Drug Discov. 2003 May;2(5):347-60
pubmed: 12750738
Adv Drug Deliv Rev. 2014 Feb;66:42-57
pubmed: 24060923
Adv Funct Mater. 2015 Jan 7;25(1):36-43
pubmed: 25729344
Mol Cancer Res. 2006 Dec;4(12):927-34
pubmed: 17189383
Nanomedicine. 2016 Jan;12(1):81-103
pubmed: 26370707
Pharmaceutics. 2018 Oct 09;10(4):
pubmed: 30304861
Adv Drug Deliv Rev. 2013 May;65(5):689-702
pubmed: 22921598
Cancer Res. 2007 Sep 1;67(17):8156-63
pubmed: 17804728
Acta Pharm Sin B. 2014 Jun;4(3):193-201
pubmed: 26579383
Pharm Res. 2014 Jun;31(6):1390-406
pubmed: 24595494
Adv Drug Deliv Rev. 2013 May;65(5):622-48
pubmed: 22975010
Drug Deliv. 2016 Oct;23(8):2720-2725
pubmed: 26203691
Drug Deliv. 2016 Nov;23(9):3408-3416
pubmed: 27181462
Cancer Cell. 2008 Jun;13(6):472-82
pubmed: 18538731
Cells. 2019 Aug 09;8(8):
pubmed: 31405017
J Control Release. 2015 May 28;206:49-57
pubmed: 25724273
Adv Mater. 2011 Sep 22;23(36):H217-47
pubmed: 21842473
Biomed Res Int. 2014;2014:207974
pubmed: 24971317
Colloids Surf B Biointerfaces. 2017 Apr 1;152:277-288
pubmed: 28122295
Colloids Surf B Biointerfaces. 2018 Jan 1;161:302-313
pubmed: 29096375
Nanoscale. 2015 Jun 7;7(21):9487-96
pubmed: 25909483
Stem Cell Res Ther. 2017 Mar 9;8(1):53
pubmed: 28279193
Clin Cancer Res. 2006 Dec 15;12(24):7261-70
pubmed: 17189397
Theranostics. 2014 Mar 26;4(6):660-77
pubmed: 24723986
Nanomedicine (Lond). 2014 Jul;9(9):1277-80
pubmed: 25204816
Mol Pharm. 2010 Dec 6;7(6):1921-9
pubmed: 20964352
J Korean Neurosurg Soc. 2015 May;57(5):323-8
pubmed: 26113958
Biomaterials. 2013 Apr;34(12):2969-79
pubmed: 23380351
J Control Release. 2016 Aug 10;235:34-47
pubmed: 27208862
Nanomedicine (Lond). 2011 Apr;6(3):529-44
pubmed: 21542690
Int J Pharm. 2012 Feb 28;423(2):509-15
pubmed: 22178618
Trends Biotechnol. 2011 Jul;29(7):323-32
pubmed: 21489647
Int J Pharm. 2016 Feb 29;499(1-2):10-19
pubmed: 26721730
Int J Nanomedicine. 2018 Mar 15;13:1601-1610
pubmed: 29588587
Theranostics. 2018 May 11;8(12):3284-3307
pubmed: 29930730
Oncotarget. 2017 May 18;8(40):66889-66900
pubmed: 28978003
J Control Release. 2012 Jun 10;160(2):254-63
pubmed: 22245688
Pharmacol Res. 2010 Aug;62(2):115-25
pubmed: 20097288
Cancers (Basel). 2011 Jun 10;3(2):2655-66
pubmed: 21796273

Auteurs

Michele d'Angelo (M)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Vanessa Castelli (V)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Elisabetta Benedetti (E)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Andrea Antonosante (A)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Mariano Catanesi (M)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Reyes Dominguez-Benot (R)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Giuseppina Pitari (G)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Rodolfo Ippoliti (R)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.

Annamaria Cimini (A)

Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Department of Biology, Sbarro Institute for Cancer Research and Molecular Medicine, Temple University, Philadelphia, PA, United States.

Classifications MeSH